EUVIMEDEUVIMED entdecken
Crossref

Ocular surface disease management in cataract surgery

Alessandro Mularoni, Antonio Di Zazzo, Daniele Gaudenzi, Francesco Cutrupi, Francesco Gaudenzi, Giovanna Linda Possati

Archives of Clinical and Experimental Ophthalmology · 2025

DOI: 10.46439/ophthalmology.7.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Clinical and Experimental Ophthalmology, 2025. Verfasst von Alessandro Mularoni und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

According to the literature, 80% of patients undergoing cataract surgery suffer from ocular surface disease (OSD). Along with postoperative refractive surprise, the onset of OSD is the main cause of dissatisfaction in cataract surgery patients, accounting for 35% of cases. These patients are characterized by persistent dysregulation of ocular surface para-inflammation, leading to chronic low- grade inflammation with significant consequences on daily activities and work productivity. This study aims to investigate the effects of topical desonide sodium phosphate 0.025% eye drops on the signs and symptoms of OSD in patients undergoing cataract surgery.

Methods

A multi center randomized controlled trial was conducted. Cataract patients without ocular comorbidities were consecutively enrolled and randomized into two groups. Both groups underwent phacoemulsification with standard postoperative therapy (levofloxacin 0.5% eye drops six times a day for 5 days and dexamethasone sodium phosphate 0.15% eye drops four times a day for 1 week and then twice a day for 1 week). Additionally, the study group received lubricating eye drops containing xanthan gum 0.2% and desonide sodium phosphate 0.025% three times a day, while the control group received hyaluronic acid 0.15% three times a day. At patient enrollment (T0), 1 day (T1), 2 weeks (T2), and 1 month after surgery (T3), signs and symptoms of OSD and tear function tests were recorded.

Results

OSDI scores significantly worsened at T1 in both groups (study: 28.4 ± 2.1 to 75.7 ± 5.7; control: 26.3 ± 1.8 to 68.0 ± 6.9; p

Zitieren

APA

Mularoni, A., Zazzo, A. D., Gaudenzi, D., Cutrupi, F., Gaudenzi, F., & Possati, G. L. (2025). Ocular surface disease management in cataract surgery. Archives of Clinical and Experimental Ophthalmology. https://doi.org/10.46439/ophthalmology.7.035

Vancouver

Mularoni A, Zazzo AD, Gaudenzi D, Cutrupi F, Gaudenzi F, Possati GL. Ocular surface disease management in cataract surgery. Archives of Clinical and Experimental Ophthalmology. 2025. doi:10.46439/ophthalmology.7.035

BibTeX
@article{Mularoni2025,
  author = {Mularoni, Alessandro and Zazzo, Antonio Di and Gaudenzi, Daniele and Cutrupi, Francesco and Gaudenzi, Francesco and Possati, Giovanna Linda},
  title = {Ocular surface disease management in cataract surgery},
  journal = {Archives of Clinical and Experimental Ophthalmology},
  year = {2025},
  doi = {10.46439/ophthalmology.7.035}
}
Kostenlos starten →